EpicentRx Presents Updates on its Oncology Clinical Development Programs at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Company details follow-on Phase 2b study design in head and neck cancer for its lead small molecule candidate, RRx-001 Company also presented positive first-in-human data from its TGF-β trap vector, AdAPT-001 TORREY PINES, Calif., June 2, 2023 /PRNewswire/ — EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, today presented clinical progress updates for two lead … Read more